Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas

• Published in: Modern pathology Vol. 28; no. 12; pp. 1545 - 1554
• Main Authors: Liau, Jau-Yu, Lee, Jen-Chieh, Tsai, Jia-Huei, Yang, Ching-Yao, Liu, Tsung-Lin, Ke, Zhi-Long, Hsu, Hung-Han, Jeng, Yung-Ming
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.12.2015; Elsevier Limited
• Subjects: 631/67/1798; Adaptor Proteins, Signal Transducing - analysis; Adaptor Proteins, Signal Transducing - biosynthesis; Blood diseases; Co-Repressor Proteins; Cytogenetics; DNA Helicases - analysis; DNA Helicases - biosynthesis; Ewings sarcoma; Genotype & phenotype; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Intellectual disabilities; Laboratory Medicine; Liposarcoma; Medicine; Medicine & Public Health; Molecular Chaperones; Mutation; Neuroendocrine tumors; Nuclear Proteins - analysis; Nuclear Proteins - biosynthesis; original-article; Pathology; Phenotype; Sarcoma - genetics; Sarcoma - pathology; Soft Tissue Neoplasms - genetics; Soft Tissue Neoplasms - pathology; Telomerase; Telomere - genetics; Telomere Homeostasis - physiology; X-linked Nuclear Protein; Yeast; Taiwan
• ISSN: 0893-3952; 1530-0285
• DOI: 10.1038/modpathol.2015.114

According to cytogenetic aberrations, sarcomas can be categorized as complex or simple karyotype tumors. Alternative lengthening of telomeres is a telomere-maintenance mechanism common in sarcomas. Recently, this mechanism was found to be associated with loss of either α-thalassemia/mental retardation syndrome X-linked (ATRX) or death domain-associated (DAXX) protein. We previously reported that alternative lengthening of telomeres and loss of ATRX expression were common in leiomyosarcoma, angiosarcoma, pleomorphic liposarcoma, and dedifferentiated liposarcoma. In the present study, we screened an additional 245 sarcomas of other types to determine the prevalence of alternative lengthening of telomeres, loss of ATRX/DAXX expression, and their relationship. Undifferentiated pleomorphic sarcomas were frequently alternative lengthening of telomeres positive (65%) and loss of ATRX was seen in approximately half of the alternative lengthening of telomeres-positive tumors. Nineteen of 25 myxofibrosarcomas were alternative lengthening of telomeres-positive, but only one was ATRX deficient. Three of 15 radiation-associated sarcomas were alternative lengthening of telomeres positive, but none of them was ATRX deficient. Alternative lengthening of telomeres and/or loss of ATRX were uncommon in malignant peripheral nerve sheath tumors, gastrointestinal stromal tumors, and embryonal rhabdomyosarcomas. By contrast, none of the 71 gene fusion-associated sarcomas was ATRX deficient or alternative lengthening of telomeres positive. All tumors exhibited preserved DAXX expression. Combining our previous studies and this study, a total of 384 sarcomas with complex karyotypes were examined, 83 of which were ATRX deficient (22%). By telomere-specific fluorescence in situ hybridization, 45% (138/308) were alternative lengthening of telomeres positive, 55% (76/138) of which were ATRX deficient. Loss of ATRX was highly associated with alternative lengthening of telomeres ( P <0.001). We conclude that alternative lengthening of telomeres is a frequent telomere-maintenance mechanism in cytogenetically complex sarcomas. Loss of ATRX is highly associated with this feature.